BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer

  • Kim, Da-Hyun (Department of Biochemistry & Molecular Biology, Yonsei University College of Medicine) ;
  • Lee, Seul (Department of Biochemistry & Molecular Biology, Yonsei University College of Medicine) ;
  • Kang, Hyeok Gu (Department of Biochemistry & Molecular Biology, Yonsei University College of Medicine) ;
  • Park, Hyun-Woo (Department of Biochemistry, College of Life Science, Yonsei University) ;
  • Lee, Han-Woong (Department of Biochemistry, College of Life Science, Yonsei University) ;
  • Kim, Dongin (R&D center, ABL Bio Inc.) ;
  • Yoem, Dong-Hoon (R&D center, ABL Bio Inc.) ;
  • Ahn, Jin-Hyung (R&D center, ABL Bio Inc.) ;
  • Ha, Eunsin (R&D center, ABL Bio Inc.) ;
  • You, Weon-Kyoo (R&D center, ABL Bio Inc.) ;
  • Lee, Sang Hoon (R&D center, ABL Bio Inc.) ;
  • Kim, Seok-Jun (Department of Biomedical Science, College of Natural Science, Chosun University) ;
  • Chun, Kyung-Hee (Department of Biochemistry & Molecular Biology, Yonsei University College of Medicine)
  • Received : 2020.05.13
  • Accepted : 2020.05.27
  • Published : 2020.10.31
Download PDF
⟨ Previous Next ⟩

Abstract

Notch signaling has been identified as a critical pathway in gastric cancer (GC) progression and metastasis, and inhibition of Delta-like ligand 4 (DLL4), a Notch ligand, is suggested as a potent therapeutic approach for GC. Expression of both DLL4 and vascular endothelial growth factor receptor 2 (VEGFR2) was similar in the malignant tissues of GC patients. We focused on vascular endothelial growth factor (VEGF), a known angiogenesis regulator and activator of DLL4. Here, we used ABL001, a DLL4/VEGF bispecific therapeutic antibody, and investigated its therapeutic effect in GC. Treatment with human DLL4 therapeutic antibody (anti-hDLL4) or ABL001 slightly reduced GC cell growth in monolayer culture; however, they significantly inhibited cell growth in 3D-culture, suggesting a reduction in the cancer stem cell population. Treatment with anti-hDLL4 or ABL001 also decreased GC cell migration and invasion. Moreover, the combined treatment of irinotecan with anti-hDLL4 or ABL001 showed synergistic antitumor activity. Both combination treatments further reduced cell growth in 3D-culture as well as cell invasion. Interestingly, the combination treatment of ABL001 with irinotecan synergistically reduced the GC burden in both xenograft and orthotopic mouse models. Collectively, DLL4 inhibition significantly decreased cell motility and stem-like phenotype and the combination treatment of DLL4/VEGF bispecific therapeutic antibody with irinotecan synergistically reduced the GC burden in mouse models. Our data suggest that ABL001 potentially represents a potent agent in GC therapy. Further biochemical and pre-clinical studies are needed for its application in the clinic.

Keywords

References

  1. Russo AE and Strong VE (2019) Gastric cancer etiology and management in asia and the west. Annu Rev Med 70, 353-367 https://doi.org/10.1146/annurev-med-081117-043436
  2. Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R and Polkowski WP (2018) Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 10, 239-248 https://doi.org/10.2147/CMAR.S149619
  3. Kanat O, O'Neil B and Shahda S (2015) Targeted therapy for advanced gastric cancer: A review of current status and future prospects. World J Gastrointest Oncol 7, 401-410 https://doi.org/10.4251/wjgo.v7.i12.401
  4. Lin Y, Wu Z, Guo W and Li J (2015) Gene mutations in gastric cancer: a review of recent next-generation sequencing studies. Tumour Biol 36, 7385-7394 https://doi.org/10.1007/s13277-015-4002-1
  5. Guruharsha KG, Kankel MW and Artavanis-Tsakonas S (2012) The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet 13, 654-666 https://doi.org/10.1038/nrg3272
  6. Andersson ER, Sandberg R and Lendahl U (2011) Notch signaling: simplicity in design, versatility in function. Development 138, 3593-3612 https://doi.org/10.1242/dev.063610
  7. Hori K, Sen A and Artavanis-Tsakonas S (2013) Notch signaling at a glance. J Cell Sci 126, 2135-2140 https://doi.org/10.1242/jcs.127308
  8. Bagheri V, Memar B, Behzadi R et al (2018) Isolation and identification of chemotherapy-enriched sphere-forming cells from a patient with gastric cancer. J Cell Physiol 233, 7036-7046 https://doi.org/10.1002/jcp.26627
  9. Ishigami S, Arigami T, Uenosono Y et al (2013) Clinical implications of DLL4 expression in gastric cancer. J Exp Clin Cancer Res 32, 46 https://doi.org/10.1186/1756-9966-32-46
  10. Miao ZF, Xu H, Xu HM et al (2017) DLL4 overexpression increases gastric cancer stem/progenitor cell self-renewal ability and correlates with poor clinical outcome via Notch-1 signaling pathway activation. Cancer Med 6, 245-257 https://doi.org/10.1002/cam4.962
  11. Aster JC, Pear WS and Blacklow SC (2017) The Varied Roles of Notch in Cancer. Annu Rev Pathol 12, 245-275 https://doi.org/10.1146/annurev-pathol-052016-100127
  12. Lee D, Kim D, Choi YB et al (2016) Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis. MAbs 8, 892-904 https://doi.org/10.1080/19420862.2016.1171432
  13. Bailly C (2019) Irinotecan: 25 years of cancer treatment. Pharmacol Res 148, 104398 https://doi.org/10.1016/j.phrs.2019.104398
  14. Thuss-Patience PC, Kretzschmar A, Bichev D et al (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47, 2306-2314 https://doi.org/10.1016/j.ejca.2011.06.002
  15. Pasquini G, Vasile E, Caparello C et al (2016) Third-line chemotherapy with irinotecan plus 5-fluorouracil in caucasian metastatic gastric cancer patients. Oncology 91, 311-316 https://doi.org/10.1159/000443962
  16. Seo MD, Lee KW, Lim JH et al (2008) Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Jpn J Clin Oncol 38, 589-595 https://doi.org/10.1093/jjco/hyn078
  17. Sweeney TJ, Mailander V, Tucker AA et al (1999) Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A 96, 12044-12049 https://doi.org/10.1073/pnas.96.21.12044
  18. den Dulk M, Verheij M, Cats A, Jansen EP, Hartgrink HH and Van de Velde CJ (2006) The essentials of locoregional control in the treatment of gastric cancer. Scand J Surg 95, 236-242 https://doi.org/10.1177/145749690609500405
  19. Reim D, Loos M, Vogl F et al (2013) Prognostic implications of the seventh edition of the international union against cancer classification for patients with gastric cancer: the Western experience of patients treated in a single-center European institution. J Clin Oncol 31, 263-271 https://doi.org/10.1200/JCO.2012.44.4315
  20. Kim IH (2019) Current status of adjuvant chemotherapy for gastric cancer. World J Gastrointest Oncol 11, 679-685 https://doi.org/10.4251/wjgo.v11.i9.679
  21. Fujita K, Kubota Y, Ishida H and Sasaki Y (2015) Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 21, 12234-12248 https://doi.org/10.3748/wjg.v21.i43.12234
  22. Chun JH, Kim HK, Lee JS et al (2004) Weekly irinotecan in patients with metastatic gastric cancer failing cisplatinbased chemotherapy. Jpn J Clin Oncol 34, 8-13 https://doi.org/10.1093/jjco/hyh006
  23. Yamao T, Shirao K, Matsumura Y et al (2001) Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer. Ann Oncol 12, 1729-1735 https://doi.org/10.1023/A:1013525531664
  24. Leslie JD, Ariza-McNaughton L, Bermange AL, McAdow R, Johnson SL and Lewis J (2007) Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 134, 839-844 https://doi.org/10.1242/dev.003244
  25. Shutter JR, Scully S, Fan W et al (2000) Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev 14, 1313-1318
  26. Chatterjee S, Heukamp LC, Siobal M et al (2013) Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest 123, 1732-1740 https://doi.org/10.1172/JCI65385
  27. Fu L, Bu L, Yasuda T et al (2020) Gastric cancer stem cells: current insights into the immune microenvironment and therapeutic targets. Biomedicines 8, 7 https://doi.org/10.3390/biomedicines8010007
  28. Katoh M and Katoh M (2020) Precision medicine for human cancers with Notch signaling dysregulation (Review). Int J Mol Med 45, 279-297
  29. Baek JH, Kim NJ, Song JK and Chun KH (2017) Kahweol inhibits lipid accumulation and induces Glucose-uptake through activation of AMP-activated protein kinase (AMPK). BMB Rep 50, 566-571 https://doi.org/10.5483/BMBRep.2017.50.11.031
  30. Kim NJ, Baek JH, Lee J, Kim H, Song JK and Chun KH (2019) A PDE1 inhibitor reduces adipogenesis in mice via regulation of lipolysis and adipogenic cell signaling. Exp Mol Med 51, 5 https://doi.org/10.1038/s12276-018-0198-7
  31. Cho Y, Kang HG, Kim SJ et al (2018) Post-translational modification of OCT4 in breast cancer tumorigenesis. Cell Death Differ 25, 1781-1795 https://doi.org/10.1038/s41418-018-0079-6